Advanced Therapies Europe 2025
Cell & Gene Therapy Insights 2025; 11(6), 839–841
DOI: 10.18609/cgti.2025.094
As part of our ongoing coverage of major gatherings in the advanced therapeutics space, Cell & Gene Therapy Insights presents a preview of Advanced Therapies Europe 2025. Scheduled for September 2–4, 2025, in Barcelona, Spain, this conference will see 500 senior leaders from biotech, pharma, academia, investment, manufacturing, and solution provider sectors gather together to explore the latest advancements in cell and gene therapy.
The event includes deep-dive workshops, strategic roundtables, the Women in Advanced Therapies Congress, the Investment Summit, and the Innovation Exchange showcasing the biotech breakthroughs shaping our future. Confirmed speakers include leaders from Takeda, Novartis, Johnson & Johnson, Kiji Therapeutics, and more.
Emerging technologies: from concept to disruption
Advanced Therapies Europe 2025 will spotlight the technologies poised to redefine the CGT landscape. In the panel ‘Emerging Tech in CGT—What’s Next?’, leaders including Åse Rosenqvist (Nordic Cell Therapy Business Unit Lead, Johnson & Johnson), David Sourdive (Co-founder, Executive Vice President CMC & Manufacturing, Cellectis), Carolina Pola (CEO, STAb Therapeutics), and Oliver Dovey (Senior Director Functional Genomics, bit.bio) will explore the frontiers of CRISPR, gene editing, and cell engineering. The session will examine the next wave of in vivo and ex vivo therapies, and ask which breakthroughs are most likely to shift the clinical and commercial paradigm.
In addition, the ‘Innovation Exchange’ will offer a dynamic platform for biotech start-ups to pitch novel solutions to a panel of investors including Sven Kili (Partner, Saisei Ventures), Rahul Khetan (Venture Associate, UCB Ventures), Laura Rodriguez Gallego (Partner, Invivo Partners), and Malgorzata Rogalska (Analyst, Ysios Capital). This session promises a window into the technologies that may soon move from the edge of possibility to the center of practice.
Manufacturing, analytics, & scale-up
As CGT products move from lab to clinic, the challenges of manufacturing, characterization, and realistic development timelines remain front and center. In the panel ‘Bridging the Characterization & Analytics Gap in CGT’, experts including Eleuterio Lombardo (Director, Cell Therapy Characterization, Takeda), Lindsay Davies (Chief Scientific Officer, NextCell Pharma), and Damian Marshall (VP, Analytical Development, Resolution Therapeutics) will explore why robust analytics remain a bottleneck, and how collaborative, cross-functional approaches are beginning to close the gap.
Furthermore, ‘From Discovery to Development—Creating Realistic CGT Timelines’ brings together voices from biotech, academia, and clinical translation. Speakers Anne Douar (Principal & Founder, Ad hoc Biologics), John Campbell (Chief Scientific Officer, Swarm Oncology), Elena Matsa (Professor, University College Cork), Alessandra Magnani (Head, Advanced Therapies and Immunotherapy Platform, Hospital Sant Joan de Déu), and Claudio Santos (CEO, Gyala Therapeutics) will discuss how to align CMC, regulatory, and development planning from day 1.
Regulatory affairs: navigating complexity with clarity
As the regulatory landscape for advanced therapies continues to evolve, two sessions at Advanced Therapies Europe 2025 will provide essential insights for developers seeking clarity and strategic foresight. In ‘CGT Regulations Uncovered: New Rules, New Realities’, Alexander Natz (Secretary General, EUCOPE) and Paolo Morgese (Vice President Public Affairs Europe, Alliance for Regenerative Medicine) will unpack recent legislative shifts across the EU, USA, and other key regions. From the EU Pharmaceutical Legislation reform to the implications of the FDA’s evolving stance on accelerated pathways, this session offers a practical lens on compliance in a fast-moving field.
The panel ‘Engaging Regulators Early—The Key to Accelerating ATMP Development’ will explore how early, proactive dialogue with agencies like the EMA, US FDA, and MHRA can de-risk development. Anna Koptina (Head of Regulatory Affairs, Elicera Therapeutics) and Benjamin Dewees (Senior Vice President of Regulatory Affairs, Artiva Biotherapeutics) will share lessons from the front lines of regulatory engagement—highlighting what works, what doesn’t, and why timing is everything.
A look to the future: where are we heading?
As the conference draws to a close, the plenary panel discussion ‘Charting The way Forward: Where Are We Heading?’ will see Angela Vollstedt (Director, Global Cell & Gene Therapies Portfolio, Novartis), Miguel Forte (CEO, Kiji Therapeutics and President, ISCT), and Montse Daban (Executive Director, BIOCAT) debate the future trajectory of advanced therapies. This panel of trailblazers from across the field will reflect on 2 days of deep discussions on the current state of the European CGT landscape, and look forward to the future of the space. Attendees can expect discussion on Europe’s global competitiveness in CGT, the role of AI and automation in reshaping development pipelines, and how to build a more resilient and equitable innovation ecosystem.
As a reader of Cell & Gene Therapy Insights, you’re entitled to a 20% discount on delegate tickets—just use the code INSIGHTSBIO20. You can use the link here to register for Advanced Therapies Europe 2025.
Additionally, to find out what other cell and gene therapy events are upcoming, you can find our online Events Calendar here.